Subsidized Genetic Testing for HBOC Launching December 1, 2026

Access to Subsidized Genetic Testing

Starting December 1, 2026, individuals at risk of hereditary breast and ovarian cancer (HBOC) will have the opportunity to undergo subsidized genetic testing across three public healthcare facilities in Singapore. This initiative was announced by the Ministry of Health (MOH) on October 5, 2023.

Objective of the Initiative

The subsidization of genetic testing for HBOC is part of a larger strategy by the MOH to strengthen preventive healthcare services in Singapore. According to Health Minister Ong Ye Kung, approximately one in 150 individuals in Singapore may carry a gene mutation that increases the risk of these cancers. It is estimated that around 2,000 individuals will be eligible for this testing.

Financial Support Details

The program provides up to 70% subsidy for genetic testing costs through a means-testing framework. Additionally, individuals can utilize their MediSave accounts to cover the remaining costs. Starting in the latter half of 2026, patients opting for preventive surgical measures, such as mastectomies or oophorectomies, will also find financial assistance through MediShield Life and MediSave.

Where to Get Tested

These subsidized tests will be available at cancer specialist outpatient clinics located in:

• National Cancer Centre Singapore
• National University Cancer Institute, Singapore
• Tan Tock Seng Hospital

Testing is recommended for individuals diagnosed with breast and/or ovarian cancer carrying risk factors for HBOC, first-degree relatives of gene carriers, and those with significant family histories suggesting HBOC.

Understanding Eligibility and Support

Singaporeans and permanent residents qualifying for the program will enjoy substantial financial assistance, with additional support available for seniors from the Pioneer and Merdeka Generations. Furthermore, from January 2024, revised Medisave limits will be in effect to make the genetic testing process more affordable.

Before the enhanced scheme is fully implemented, existing Medisave limits will be expanded to encompass HBOC genetic tests. Seniors aged 60 and above can utilize Flexi-Medisave to mitigate added costs, if necessary.

For families, healthcare professionals will recommend genetic testing for first-degree relatives of those who test positive, allowing for cascade testing supported by the same subsidies and MediSave options. The MOH emphasizes that individuals with sufficient Medisave balances could potentially incur no out-of-pocket expenses for their genetic testing.

Importance of Genetic Understanding and Action

Understanding one’s genetic risk is just the beginning; taking preventative action through various interventions is crucial. Options such as risk-reducing mastectomy (RRM) can significantly lower breast cancer risk by over 90% for those with HBOC-related mutations, while risk-reducing bilateral salpingo-oophorectomy (RRBSO) can decrease ovarian cancer risk by more than 80%.

The MOH previously announced that MediShield Life would extend coverage to preventive surgeries in certain scenarios, with MediSave provisions being similarly applied to RRM and RRBSO. Coverage for RRM has already been effective since September 2026, and the same will apply to RRBSO by the year’s end.

Affordable Subsequent Care

MOH is also committed to ensuring the affordability of yearly surveillance measures like MRI or mammogram screenings and pharmaceutical therapies. By broadening access to genetic testing and subsequent preventive measures, the ministry aims to lessen the impact of hereditary cancers on individuals and the healthcare system as a whole.

Ongoing evaluations of these initiatives will be undertaken to ensure even more Singaporeans can reap the benefits of early detection and timely intervention in years to come.